Meds & supplements › Tobramycin
Medicine
Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa.
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
TOBI is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa.
Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) < 25% or > 75% predicted, or patients colonized with Burkholderia cepacia.
The following serious adverse reactions are described below and elsewhere in the labeling:
TOBI is contraindicated in patients with a known hypersensitivity to any aminoglycoside.
sofidex [Internet]. Daloreum; c2026. Tobramycin; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/tobramycin
sofidex. (2026, August 3). Tobramycin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/tobramycin
Tobramycin. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/tobramycin
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.